Gapping up
In reaction to earnings/guidance:
- SAIC +6%, ODFL +0.7% (Q2 update)
Other news:
- ASPN +12.6% (provides FY22 business update)
- CSIQ +5.9% (sells 70% Stake in 738 MWp Solar Projects to SPIC Brasil)
- SAVE +4.6% (JetBlue Airways submits improved proposal to acquire Spirit Airlines)
- HUT +3.9% (reports 7078 self-mined Bitcoin in reserve after 309 were generated in May)
- TOI +3.1% (files for 1342076 share common stock offering by selling shareholders)
- TSLA +2.7% (Elon Musk tweets "Total headcount will increase but salaried should be fairly flat")
- ARQT +2.6% (topline results from STRATUM pivotal phase 3 trial of roflumilast foam 0.3%)
- PK +2.2% (provides operating trends in Q2 update)
- BCRX +2.2% (Health Canada has authorized ORLADEYO (berotralstat) as prevention of recurrent hereditary angioedema (HAE) attacks)
- VERU +2.1% (presentation of final positive phase 1b/2 clinical trial results for sabizabulin in metastatic castration resistant prostate cancer at the 2022 American Society of Clinical Oncology Annual Meeting)
- SBUX +1.9% (Board of Directors affirms CEO transition details; Board reiterates plans of driving toward naming new leader in Fall)
- EPR +1.6% (files mixed securities shelf offering)
- DNA +1.4% (acquired certain assets from Bitome)
- GSK +1.3% (receives FDA approval of Priorix for the prevention of measles mumps and rubella in individuals 12 months of age and older)
- ET +1.2% (signs LNG sale and purchase agreement with China Gas)
Analyst comments:
- SPOT +5% (upgraded to Outperform from Mkt Perform at Raymond James)
- AMSWA +3.9% (upgraded to Buy from Neutral at B. Riley Securities)
- AMBP +3.7% (upgraded to Overweight from Equal Weight at Barclays)
- CRWD +2.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ACB +1.9% (upgraded to Hold from Sell at Stifel)
- AXP +1.4% (upgraded to Buy from Hold at Edward Jones)
- RMD +1.2% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- LULU +1.1% (upgraded to Mkt Perform from Underperform at Bernstein)